Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study. (Chest, 2013)

(untitled) - Fazio, N; Granberg, D; Grossman, A; Saletan, S; Klimovsky, J; Panneerselvam, A; Wolin, E